iOncologi Welcomes New Board Members to Advance Immunotherapy Technologies
iOncologi, a leading biopharmaceutical company dedicated to developing innovative immunotherapies for solid tumors, is pleased to announce the appointment of Dr. Mona Flores and Mr. Paolo Fundarò to its Board of Directors. Dr. Flores and Mr. Fundarò bring a wealth of expertise and experience in the fields of AI-guided healthcare solutions and life sciences investment, respectively. Their addition to the board aligns with iOncologi’s commitment to accelerating the development of next-generation transformative immunotherapies for solid tumors.
Dr. Mona Flores, a globally recognized leader in artificial intelligence (AI) and digital healthcare transformation, joins the board with a background in AI-driven healthcare solutions and strategic innovation. With experience as the Global Head of Medical AI at NVIDIA and a board-certified cardiac surgeon, Dr. Flores brings a unique perspective to iOncologi’s approach to developing cutting-edge cancer therapies.
Mr. Paolo Fundarò, a seasoned life sciences investor and executive, adds his expertise in biopharmaceutical company leadership and strategic financing to the board. As the Founder and Managing Partner of XGEN Venture, a life sciences-focused VC firm, Mr. Fundarò’s financial and operational knowledge will play a key role in shaping iOncologi’s corporate strategy and expansion efforts.
Dr. Duane A. Mitchell, Co-founder of iOncologi and Chairman of the Board, expressed excitement about welcoming Dr. Flores and Mr. Fundarò to the board. He highlighted Dr. Flores’ leadership and operational experience in medical AI and Mr. Fundarò’s industry-leading experience as valuable additions to the iOncologi team.
The appointment of Dr. Flores and Mr. Fundarò underscores iOncologi’s commitment to assembling a world-class leadership team dedicated to advancing AI-guided, next-generation immunotherapies for solid tumors. As the company continues to focus on harnessing the power of the immune system to create innovative oncology treatments, the expertise of Dr. Flores and Mr. Fundarò will be instrumental in driving forward the development of transformative cancer therapies.
In conclusion, the addition of Dr. Mona Flores and Mr. Paolo Fundarò to iOncologi’s Board of Directors marks an exciting new chapter in the company’s mission to revolutionize cancer treatment. Their expertise and experience will play a crucial role in advancing the development of next-generation immunotherapies for solid tumors. Stay tuned for more updates from iOncologi as we continue our journey towards improving patient outcomes through innovative cancer therapies. Visit www.ioncologi.com for more information about iOncologi, Inc.
